Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson’s disease: the impact of ethnicity and onset age

Neurological Sciences

Volumn 36, Issue 2, 2015, Pages 179-188

  Liu, Ying ^a   Chen, Yan Yan ^a   Liu, Hui ^a   Yao, Ci Jiang ^a   Zhu, Xiao Xia ^a   Chen, Dao Jun ^a   Yang, Jin ^a   Lu, You Jin ^a   Cao, Ji Yu ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Parkinson s disease; Polymorphism; UCHL1

Indexed keywords

UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; UCHL1 PROTEIN, HUMAN;

AMERICAN; ARTICLE; ASIAN; DISEASE PREDISPOSITION; ETHNICITY; EUROPEAN; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MANTEL HAENSZEL TEST; META ANALYSIS; ONSET AGE; PARKINSON DISEASE; PUBLISHING; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; UNITED STATES;

AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; UBIQUITIN THIOLESTERASE; UNITED STATES;

EID: 84922071307     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1987-y     Document Type: Article

References (53)

1. Klein C, Schlossmacher MG (2006) The genetics of Parkinson disease: implications for neurological care. Nat Clin Pract Neurol 2:136–146
2. Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23:228–242
3. Roemmich RT, Nocera JR, Stegemoller EL, Hassan A, Okun MS, Hass CJ (2014) Locomotor adaptation and locomotor adaptive learning in Parkinson’s disease and normal aging. Clin Neurophysiol 125:313–319
4. Tsuboi Y (2012) Environmental-genetic interactions in the pathogenesis of Parkinson’s disease. Exp Neurobiol 21:123–128
5. Chai C, Lim KL (2013) Genetic insights into sporadic Parkinson’s disease pathogenesis. Curr Genomics 14:486–501
6. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 26(Suppl 1):S1–S58
7. Poulopoulos M, Levy OA, Alcalay RN (2012) The neuropathology of genetic Parkinson’s disease. Mov Disord 27:831–842
8. Klein C (2006) Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 63:328–334
9. Manfredsson FP, Okun MS, Mandel RJ (2009) Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson’s disease. Curr Gene Ther 9:375–388
10. Tseng WE, Chen CM, Chen YC, Yi Z, Tan EK, Wu YR (2013) Genetic variations of GAK in two Chinese Parkinson’s disease populations: a case-control study. PLoS One 8:e67506
11. Xu X, Wang N, Xu H, Xie A, Jiang H, Xie J (2013) Fibroblast growth factor 20 polymorphism in sporadic Parkinson’s disease in Northern Han Chinese. J Clin Neurosci 20:1588–1590
12. Gobel A, Macklin EA, Winkler S, Betensky RA, Klein C, Lohmann K et al (2012) Genetic risk factors in Parkinson’s disease: single gene effects and interactions of genotypes. J Neurol 259:2503–2505
13. Tian JY, Guo JF, Wang L, Sun QY, Yao LY, Luo LZ et al (2012) Mutation analysis of LRRK2, SCNA, UCHL1, HtrA2 and GIGYF2 genes in Chinese patients with autosomal dorminant Parkinson’s disease. Neurosci Lett 516:207–211
14. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395:451–452
15. Lincoln S, Vaughan J, Wood N, Baker M, Adamson J, Gwinn-Hardy K et al (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson’s disease. Neuroreport 10:427–429
16. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease. Neurology 53:1858–1860
17. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
19. DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114
20. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
21. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9(7):811–818
22. Holm S (1979) A simple sequentially rejective bonferroni test procedure. Scand J Stat 6:65–70
23. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I et al (2002) Association studies of multiple candidate genes for Parkinson’s disease using single nucleotide polymorphisms. Ann Neurol 51:133–136
24. Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N et al (2003) Toward identification of susceptibility genes for sporadic Parkinson’s disease. J Neurol 250(Suppl 3):III40–III43
25. Zhang J, Hattori N, Leroy E, Morris HR, Kubo S, Kobayashi T et al (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson’s disease. Parkinsonism Relat Disord 6:195–197
26. Satoh J, Kuroda Y (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson’s disease in a Japanese population. J Neurol Sci 189:113–117
27. Xiao Y, Zhang B (2008) Association of the ubiquitin carboxy-terminal hydrolase-L1 genetic polymorphism with the susceptibility of Parkinson’s disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25:586–587
28. Zhang ZJ, Burgunder JM, An XK, Wu Y, Chen WJ, Zhang JH (2008) Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson’s disease in a Han-Chinese population. Neurosci Lett 442:200–202
29. Wang J, Zhao CY, Si YM, Liu ZL, Chen B, Yu L (2002) ACT and UCH-L1 polymorphisms in Parkinson’s disease and age of onset. Mov Disord 17:767–771
30. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y et al (2006) Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson’s disease. Hum Mol Genet 15:1151–1158
31. Tan EK, Puong KY, Fook-Chong S, Chua E, Shen H, Yuen Y (2006) Case–control study of UCHL1 S18Y variant in Parkinson’s disease. Mov Disord 21:1765–1768
32. Wu YR, Chen CM, Chen YC, Chao CY, Ro LS, Fung HC (2010) Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson’s disease among Taiwanese. Clin Chim Acta 411:955–958
33. Wang L, Guo JF, Nie LL, Luo L, Zuo X, Shen L et al (2011) Case-control study of the UCH-L1 S18Y variant in sporadic Parkinson’s disease in the Chinese population. J Clin Neurosci 18:541–544
34. Miyake Y, Tanaka K, Fukushima W, Kiyohara C, Sasaki S, Tsuboi Y et al (2012) UCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan. BMC Neurol 12:62
35. Mellick GD, Silburn PA (2000) The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson’s disease. Neurosci Lett 293:127–130
36. Wintermeyer P, Krüger R, Kuhn W, Müller T, Woitalla D, Berg D et al (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson’s disease patients. NeuroReport 11:2079–2082
37. Levecque C, Destée A, Mouroux V, Becquet E, Defebvre L, Amouyel P (2001) No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson’s disease. J Neural Transm 108:979–984
38. Savettieri G, De Marco EV, Civitelli D, Salemi G, Nicoletti G, Annesi G et al (2001) Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology 57:560–561
39. Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Correze JR (2003) S18Y polymorphism in the UCH-L1 gene and Parkinson’s disease: evidence for an age-dependent relationship. Mov Disord 18:130–137
40. Healy DG, Abou-Sleiman PM, Casas JP, Ahmadi KR, Lynch T, Gandhi S et al (2006) UCHL-1 is not a Parkinson’s disease susceptibility gene. Ann Neurol 59:627–633
41. Facheris M, Strain KJ, Lesnick TG, de Andrade M, Bower JH, Ahlskog JE et al (2005) UCHL1 is associated with Parkinson’s disease: a case-unaffected sibling and case-unrelated control study. Neurosci Lett 381:131–134
42. Hutter CM, Samii A, Factor SA, Nutt JG, Higgins DS, Bird TD et al (2008) Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease. Eur J Neurol 15:134–139
43. Carmine Belin A, Westerlund M, Bergman O, Nissbrandt H, Lind C, Sydow O (2007) S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson’s disease in Sweden. Parkinsonism Relat Disord 13:295–298
44. Benitez BA, Forero DA, Arboleda GH, Granados LA, Yunis JJ, Fernandez W et al (2010) Exploration of genetic susceptibility factors for Parkinson’s disease in a South American sample. J Genet 89:229–232
45. Liu J, Xiao Q, Wang Y, Xu ZM, Wang Y, Yang Q (2013) Analysis of genome-wide association study-linked loci in Parkinson’s disease of Mainland China. Mov Disord 28:1892–1895
46. Schulte C, Gasser T (2011) Genetic basis of Parkinson’s disease: inheritance, penetrance, and expression. Appl Clin Genet 4:67–80
47. Hasegawa K, Toyoshima I (2009) Causative gene and its associated gene for Parkinson disease and dystonia. Brain Nerve 61:447–463
48. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 111:209–218
49. Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Hara Y et al (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304:176–183
50. Healy DG, Abou-Sleiman PM, Wood NW (2004) Genetic causes of Parkinson’s disease: uCHL-1. Cell Tissue Res 318:189–194
51. Maraganore DM, de Andrade M, Lesnick TG, Farrer MJ, Bower JH, Hardy JA (2003) Complex interactions in Parkinson’s disease: a two-phased approach. Mov Disord 18:631–636
52. McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS et al (2008) Exploring gene-environment interactions in Parkinson’s disease. Hum Genet 123:257–265
53. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184